Frazier Life Sciences
Biotechnology
Overview
Frazier Life Sciences is a longstanding biotech investment firm with venture and public strategies partnering with and building companies developing novel therapeutics.
Investor profile
Corporate investorInvestments
1
1 of them startups
Hiring now
0
companies with open roles
Deals in 12 months
1
1 as the lead
Rounds in 12 months
2
$87M raised
Where its companies are
United Kingdom 100%
Its companies, the freshest money firstAll 1 investments
Sources: 1 rounds in the press that name it
Financials
Total raised
$1.3B
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2025 | $1.3B | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Frazier Healthcare PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Frazier Life Sciences Acquisition Corp. II Announces Completion of $75,000,000 Initial Public Offering
Read more
Report
Frazier Life Sciences Acquisition Corp. II Closes $75 Million IPO
Frazier Life Sciences Acquisition Corp. II (FLSC) said Thursday it has closed its initial public off
Read more
Report
Frazier Life Sciences Acquisition Corp. II Announces Completion of $75,000,000 Initial Public Offering
PALO ALTO, Calif., October 15, 2026--Frazier Life Sciences Acquisition Corp. II (the "Company"), a special purpose acquisition company, announced today the closing of its initial public offering of 7,500,000 Class A ordinary shares at a price of $10.00 pe
Read more
Report
Everything You Need to Know About Investing in Frazier Life Sciences Acquisition Corp. II - Ordinary Shares - Class A
See charts, data and financials for Frazier Life Sciences Acquisition Corp. II - Ordinary Shares - Class A FLSC
Read more
Report
Frazier Life Sciences Acquisition Corp. II Announces Pricing of $75,000,000 Initial Public Offering
Read more
Report
Frazier Life Sciences Acquisition Corp. II Registers Class A Shares on Nasdaq Stock Market
Read more
Report
Frazier Life Sciences Adds Over $1.1 Billion to Frazier Life Sciences Public Fund
Frazier Life Sciences Adds Over $1.1 Billion to Frazier Life Sciences Public Fund FLS News Sep 10, 2026 Oversubscribed close brings total committed capital to approximately $2.8 billion for the Frazier Life Sciences Public Fund focused on small- and mid-c
Read more
Report
Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer
The post Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer appeared first on Frazier Life Sciences.
Read more
Report
Show more news